Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154531
Status:
UNKNOWN
Last Update Posted:
2005-12-20
First Post:
2005-09-09
Brief Title:
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by Surface-Enhanced Laser DesorptionIonization SELDI
Status:
UNKNOWN
Status Verified Date:
2003-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hepatocellular carcinoma HCC has been the leading cause of cancer death in Taiwan Though Alpha-fetoprotein AFP and des-γ-carboxy prothrombinDCP are used as the tumor markers for diagnosis of HCCs Thus these two markers are not good enough for the early detection of small HCCs To improve the survival further investigations of the early diagnostic markers are still needed
SELDI is a proteomic profiling techniques in biomarker discovery Its approach has been successfully used to identify biomarkers of various cancers such as prostate cancer bladder cancer ovarian cancer lung cancer colon cancer breast cancer and pancreatic cancer
In this current project we will apply the SELDI technique to identify the HCC biomarkers Sera samples from the HCC patients and relevant controls will be collected We hope that we can find the new HCC biomarkers If biomarkers of HCC are identified this can be used to clinical application for the possible early detection of HCCs
SELDI is a proteomic profiling techniques in biomarker discovery Its approach has been successfully used to identify biomarkers of various cancers such as prostate cancer bladder cancer ovarian cancer lung cancer colon cancer breast cancer and pancreatic cancer
In this current project we will apply the SELDI technique to identify the HCC biomarkers Sera samples from the HCC patients and relevant controls will be collected We hope that we can find the new HCC biomarkers If biomarkers of HCC are identified this can be used to clinical application for the possible early detection of HCCs
Detailed Description:
Hepatocellular carcinoma HCC has been the leading cause of cancer death in Taiwan Above 6000-8000 people died of this cancer every year in Taiwan Though regular sonographic examination can early detect small HCC and there are many therapeutic modalities for HCC the therapeutic results remains unsatisfactory Though Alpha-fetoprotein AFP and des-γ-carboxy prothrombinDCP are used as the tumor markers for diagnosis of HCCs AFP is normal in around one third of small3cm HCC patients Elevated DCP activities were present in 44-476 with HCCs less than 3cm Thus these two markers are not good enough for the early detection of small HCCs To improve the survival further investigations of the early diagnostic markers are still needed
The global analysis of cellular proteins has recently been termed proteomics and is a key area if research that is developing in the postgenomic ear With respect to cancer proteomics has the potential to identify novel targets for therapy or markers for diagnosis The proteomic profiling techniques in biomarker discovery include 1 2-D PAGE MALDI-MS two-dimensional gel electrophoresis polyacrylamide gel electrophoresis matrix assisted laser desorption ionization-mass spectrometry 2 LCMSMS liquid chromatographyMSMS 3 SELDI-TOF surface-enhanced laser desorption ionization time-of-flight These techniques have their own advantages and shortcomings
SELDI is a recently descried modification of MALDI-TOP in which small amounts of protein are directly applied to a biochip coated with specific chemical matrices hydrophobic cationic anionic normal phase and so forth or biochemical molecules such as DNA oligonucleotides or purified proteins The bound proteins retained after washing are analyzed by mass spectrometry to obtain the protein fingerprint of the sample The detected proteins are displayed as a series of peaks
SELDI-TOF MS can offer high-throughput protein profiles Blood urine body fluid or tissue specimen are taken from the patients and then are applied onto different ProteinChip Arrays The differences in the protein expression profiles of two or more distinct samples are thus obtained SELDI approach has been successfully used to identify biomarkers of various cancers such as prostate cancer bladder cancer ovarian cancer lung cancer colon cancer breast cancer and pancreatic cancer
In this current project we will apply the SELDI technique to identify the HCC biomarkers Sera samples from the HCC patients and relevant controls will be collected The samples will then be applied to SELDI analysis We hope that we can find the new HCC biomarkers If biomarkers of HCC are identified this can be used to clinical application for the possible early detection of HCCs
The global analysis of cellular proteins has recently been termed proteomics and is a key area if research that is developing in the postgenomic ear With respect to cancer proteomics has the potential to identify novel targets for therapy or markers for diagnosis The proteomic profiling techniques in biomarker discovery include 1 2-D PAGE MALDI-MS two-dimensional gel electrophoresis polyacrylamide gel electrophoresis matrix assisted laser desorption ionization-mass spectrometry 2 LCMSMS liquid chromatographyMSMS 3 SELDI-TOF surface-enhanced laser desorption ionization time-of-flight These techniques have their own advantages and shortcomings
SELDI is a recently descried modification of MALDI-TOP in which small amounts of protein are directly applied to a biochip coated with specific chemical matrices hydrophobic cationic anionic normal phase and so forth or biochemical molecules such as DNA oligonucleotides or purified proteins The bound proteins retained after washing are analyzed by mass spectrometry to obtain the protein fingerprint of the sample The detected proteins are displayed as a series of peaks
SELDI-TOF MS can offer high-throughput protein profiles Blood urine body fluid or tissue specimen are taken from the patients and then are applied onto different ProteinChip Arrays The differences in the protein expression profiles of two or more distinct samples are thus obtained SELDI approach has been successfully used to identify biomarkers of various cancers such as prostate cancer bladder cancer ovarian cancer lung cancer colon cancer breast cancer and pancreatic cancer
In this current project we will apply the SELDI technique to identify the HCC biomarkers Sera samples from the HCC patients and relevant controls will be collected The samples will then be applied to SELDI analysis We hope that we can find the new HCC biomarkers If biomarkers of HCC are identified this can be used to clinical application for the possible early detection of HCCs
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None